Medication adherence and persistence in the treatment of rheumatoid arthritis with adalimumab and etanercept. Six years of analysis

Figures & data

Figure 1. Calculation of received daily dose (RDD).

Figure 2. Values of adherence for Adalimumab and Etanercept from 2007–2012.

Figure 3. Persistence for Adalimumab and Etanercept in the treatment of rheumatoid arthritis.

Table 1. Number of patients, age, sex, and sum of total days of treatment for Etanercept and Adalimumab.

	n
	2007	2008	2009	2010	2011	2012
Etanercept
n	12	22	25	20	23	21
Sex
Male	1	1	2	1	3	4
Female	11	21	23	19	20	17
Age
Median	46.5	51	53	54	56	54
Range	30–72	31–73	33–75	34–77	28–66	28–70
TDT
Median	212	314.5	320	344	352	274
Range	118–293	29–365	125–365	70–365	90–365	149–361
Adalimumab
n	9	18	27	29	23	10
Sex
Male	0	2	3	3	3	3
Female	9	16	24	26	20	7
Age
Median	54	53.5	55	53	53	58
Range	33–67	32–67	30–69	26–70	22–71	28–69
TDT
Median	328	336	282	301	334	247
Range	146–353	66–365	54–365	29–365	113–365	126–332

Table 2. RDD, PDD, and medication adherence values from 2007–2012 for Etanercept and Adalimumab in the treatment of rheumatoid arthritis.

	2007	2008	2009	2010	2011	2012
Etanercept
WRDD, Mean (SD)	5.90 (1.72)	5.81 (1.38)	6.30 (1.09)	6.36 (1.14)	6.32 (1.40)	6.87 (1.25)
WPDD, Mean (SD)	6.67 (1.15)	6.94 (0.92)	6.71 (1.23)	6.84 (1.14)	7.19 (0.25)	7.14 (0.00)
WADH, Mean (SD)	0.92 (0.33)	0.87 (0.28)	0.97 (0.25)	0.95 (0.28)	0.88 (0.20)	0.96 (0.18)
Adalimumab
WRDD, Mean (SD)	2.60 (1.06)	2.29 (0.63)	2.50 (0.67)	2.55 (0.47)	2.58 (0.50)	2.48 (0.53)
WPDD, Mean (SD)	2.84 (0.06)	2.78 (0.14)	2.81 (0.08)	2.82 (0.08)	2.85 (0.04)	2.81 (0.08)
WADH, Mean (SD)	0.92 (0.37)	0.83 (0.23)	0.89 (0.25)	0.90 (0.16)	0.90 (0.17)	0.88 (0.17)